\-\ Texto\\:\\ \ \(0\)\
\-\ large\\ sellar\\/suprasellar\\ heterogenous\\ mass\\ w\\/\\ cystic\\ component\\.\\ \\ cystic\\ component\\ hyperintense\\ on\\ t2\\ flair\\ sequence\\.\\ \\ enhancing\\ non\\-cystic\\ component\\.\ \(0\)\
\-\ pituitary\\ macroadenoma\\-pathology\\ proven\\.\\(null\\ cell\\ macroadenoma\\)\ \(0\)\
\-\ craniopharyngioma\ \(24\)\
\-\ adenocarcinoma\ \(192\)\
\-\ aneurysm\ \(644\)\
\-\ pituitary\\ adenoma\ \(19\)\
\-\ presents\\ with\\ 1\\ week\\ history\\ of\\ temporal\\ field\\ visual\\ loss\\.\ \(0\)\
\-\ the\\ cystic\\ appearance\\ and\\ mr\\ characteristics\\ were\\ suggestive\\ of\\ a\\ craniopharyngioma\\.\\ \\ the\\ fluid\\-fluid\\ level\\ and\\ acute\\ visual\\ symptoms\\ are\\ suggestive\\ of\\ intratumoral\\ hemorrhage\\ or\\ necrosis\\ in\\ a\\ pituitary\\ macroadenoma\\.\\ \\ however\\,\\ the\\ isointense\\ signal\\ on\\ the\\ t1w\\ mr\\ is\\ not\\ consistent\\ with\\ methemoglobin\\ \\-\\ that\\ would\\ be\\ expected\\ in\\ a\\ week\\-old\\ hematoma\\.\\ \\ the\\ acute\\ presentation\\ with\\ hemorrhage\\ is\\ sometimes\\ called\\ \\"pituitary\\ apoplexy\\"\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ pituitary\\:\\ 0\\.3916871617465\ \(0\)\
\-\ macroadenoma\\:\\ 0\\.3682983893580398\ \(0\)\
\-\ component\\:\\ 0\\.27291977051867783\ \(0\)\
\-\ cystic\\:\\ 0\\.2557416028168358\ \(0\)\
\-\ craniopharyngioma\\:\\ 0\\.20514156459401472\ \(0\)\
\-\ visual\\:\\ 0\\.18114605370355463\ \(0\)\
\-\ suggestive\\:\\ 0\\.17289349266014634\ \(0\)\
\-\ null\\:\\ 0\\.14932473255729833\ \(0\)\
\-\ intratumoral\\:\\ 0\\.14645599192779354\ \(0\)\
\-\ methemoglobin\\:\\ 0\\.14397097576201606\ \(0\)\
\-\ week\\:\\ 0\\.14280481572705372\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.14215099796099467\ \(0\)\
\-\ mr\\:\\ 0\\.137378234750046\ \(0\)\
\-\ apoplexy\\:\\ 0\\.12887958296660443\ \(0\)\
\-\ acute\\:\\ 0\\.11485492630837774\ \(0\)\
\-\ t1w\\:\\ 0\\.1087822935441833\ \(0\)\
\-\ sequence\\:\\ 0\\.10710458368891844\ \(0\)\
\-\ proven\\:\\ 0\\.10710458368891844\ \(0\)\
\-\ the\\:\\ 0\\.10591191877951846\ \(0\)\
\-\ heterogenous\\:\\ 0\\.09999169696470996\ \(0\)\
\-\ field\\:\\ 0\\.09977403393195156\ \(0\)\
\-\ sometimes\\:\\ 0\\.09934619952306124\ \(0\)\
\-\ called\\:\\ 0\\.09913591505796114\ \(0\)\
\-\ characteristics\\:\\ 0\\.09734319532161868\ \(0\)\
\-\ isointense\\:\\ 0\\.09605923955961612\ \(0\)\
\-\ expected\\:\\ 0\\.09570809749782429\ \(0\)\
\-\ flair\\:\\ 0\\.09031091016439045\ \(0\)\
\-\ adenocarcinoma\\:\\ 0\\.08676669651131243\ \(0\)\
\-\ adenoma\\:\\ 0\\.08463461536239844\ \(0\)\
\-\ hyperintense\\:\\ 0\\.0844437421286306\ \(0\)\
\-\ temporal\\:\\ 0\\.08154789300612891\ \(0\)\
\-\ necrosis\\:\\ 0\\.08114593402896941\ \(0\)\
\-\ aneurysm\\:\\ 0\\.08083050313601862\ \(0\)\
\-\ would\\:\\ 0\\.07514735761532171\ \(0\)\
\-\ hematoma\\:\\ 0\\.07430258427272217\ \(0\)\
\-\ presentation\\:\\ 0\\.07307745108723675\ \(0\)\
\-\ enhancing\\:\\ 0\\.06650170299502947\ \(0\)\
\-\ loss\\:\\ 0\\.06467539356501796\ \(0\)\
\-\ level\\:\\ 0\\.06412562359193517\ \(0\)\
\-\ on\\:\\ 0\\.06412312525270625\ \(0\)\
\-\ appearance\\:\\ 0\\.0639985925379367\ \(0\)\
\-\ however\\:\\ 0\\.06283317206299588\ \(0\)\
\-\ with\\:\\ 0\\.06236123827669907\ \(0\)\
\-\ of\\:\\ 0\\.06232399970172828\ \(0\)\
\-\ t2\\:\\ 0\\.06107567435298731\ \(0\)\
\-\ cell\\:\\ 0\\.0607273132769115\ \(0\)\
\-\ signal\\:\\ 0\\.06017799789424866\ \(0\)\
\-\ is\\:\\ 0\\.05814422342321406\ \(0\)\
\-\ symptoms\\:\\ 0\\.058083688391243504\ \(0\)\
\-\ consistent\\:\\ 0\\.05756134845936117\ \(0\)\
\-\ were\\:\\ 0\\.05472142328410643\ \(0\)\
\-\ large\\:\\ 0\\.05319046823592508\ \(0\)\
\-\ in\\:\\ 0\\.05281737055620546\ \(0\)\
\-\ presents\\:\\ 0\\.051067516606410686\ \(0\)\
\-\ that\\:\\ 0\\.04606862604644025\ \(0\)\
\-\ and\\:\\ 0\\.043872535486483566\ \(0\)\
\-\ be\\:\\ 0\\.04306408947934047\ \(0\)\
\-\ not\\:\\ 0\\.041908685129900765\ \(0\)\
\-\ history\\:\\ 0\\.04055853249784442\ \(0\)\
\-\ mass\\:\\ 0\\.04054955301532921\ \(0\)\
\-\ are\\:\\ 0\\.040282163686217606\ \(0\)\
\-\ or\\:\\ 0\\.03693050607723811\ \(0\)\
